Contents

Preface ................................................................. iii

1. Executive Summary .............................................. 1

2. Introduction ....................................................... 7
   2.1 Overview ..................................................... 7
   2.2 Purpose of this Report ...................................... 13
   2.3 Target Audiences of this Report ......................... 14
   2.4 Scope of this Report ........................................ 14

3. Background Information ......................................... 17
   3.1 Internal Deposition of Radionuclides ....................... 17
       3.1.1 Inhalation .............................................. 18
       3.1.2 Ingestion ............................................... 20
       3.1.3 Absorption from Skin Contamination ............... 21
       3.1.4 Absorption Through Wounds ......................... 21
   3.2 External Contamination ...................................... 22
   3.3 Effects of Weather .......................................... 22
   3.4 Complications Due to the Presence of Multiple Agents or Serious Injuries ......................... 23
   3.5 Radiological Triage .......................................... 26
   3.6 Proximity to the Incident .................................. 26
   3.7 Previous Experience with Internal Contamination .... 27
   3.8 Conclusions .................................................. 28

4. Settings in Which Persons May Become Contaminated with Radioactive Material .................. 29
   4.1 Radiological Dispersal Device ............................. 29
       4.1.1 Incident Characteristics ............................. 30
       4.1.2 Nature of Contamination ........................... 30
   4.2 Aerosol Dispersal into a Public Area .................... 31
       4.2.1 Incident Characteristics ............................. 31
       4.2.2 Nature of Contamination ........................... 31
   4.3 Contamination of Food or Water Supplies .............. 32
       4.3.1 Incident Characteristics ............................. 32
       4.3.2 Nature of Contamination ........................... 33
   4.4 Improvised Nuclear Device ................................ 33
       4.4.1 Incident Characteristics ............................. 33
       4.4.2 Nature of Contamination ........................... 35
CONTENTS / vii

7.4 Cesium-137: Clinical Decision Guide Fact Sheet ....79
7.5 Cobalt-60: Clinical Decision Guide Fact Sheet ....80
7.6 Iodine-131: Clinical Decision Guide Fact Sheet ....82
7.7 Iridium-192: Clinical Decision Guide Fact Sheet ...84
7.8 Plutonium-238: Clinical Decision Guide Fact Sheet .85
7.9 Plutonium-239: Clinical Decision Guide Fact Sheet .86
7.10 Radium-226: Clinical Decision Guide Fact Sheet ...88
7.11 Strontium-90: Clinical Decision Guide Fact Sheet ....89
7.12 Uranium: Clinical Decision Guide and Nephrotoxicity
Fact Sheet .................................................90
   7.12.1 Treatment Based on Radiological Properties of
   Uranium (CDG) ........................................90
   7.12.2 Treatment Based on Nephrotoxic Properties of
   Uranium ..................................................91
7.13 Clinical Decision Guide Technical Details ...........93
   7.13.1 Noniodine Radionuclides .....................93
   7.13.2 Iodine Radionuclides ........................94
   7.13.3 Uranium Mass and Activity Calculations ....94

8. Rapid Determination of Internal Contamination .......96
   8.1 Rapid Identification of Radionuclide(s) Involved ...97
   8.2 Screening for External Contamination .............98
   8.3 Direct (in vivo) Screening for Internal Contamination ..99
      8.3.1 Detection of Internal Contamination by Direct
      Measurement ........................................99
         8.3.1.1 GM Survey Meter ..........................101
         8.3.1.2 Whole-Body and Lung Counters ....101
      8.3.2 Hospital Equipment for the Detection and
      Quantitation of Radionuclides ....................103
         8.3.2.1 GM Survey Meter ..........................103
         8.3.2.2 Nuclear Medicine Thyroid-Uptake
         Probe .............................................104
         8.3.2.3 Portal Monitors ...........................105
         8.3.2.4 Nuclear Medicine Gamma Camera ......106
         8.3.2.5 Pulse-Height Analyzer and Radionuclide
         Windows ........................................107
      8.3.3 Measuring Internal Contamination with Hospital
      Equipment ..........................................110
         8.3.3.1 Using GM Survey Meters to Assess
         Internal Contamination with Certain
         Gamma-Emitting Radionuclides ...............110
         8.3.3.2 Using a Gamma Camera or Thyroid-
         Uptake Probe to Assess Internal
         Contamination with Certain Gamma-
         Emitting Radionuclides ..........................110
8.3.4 Wound Monitoring ............................. 112
8.4 Indirect \textit{(in vitro)} Determination of Internal Contamination .......................... 113
\hspace{0.5cm} 8.4.1 Nasal Swabs ............................. 113
\hspace{0.5cm} 8.4.2 Urine Samples .......................... 114
\hspace{0.5cm} 8.4.3 Blood Samples .......................... 115
\hspace{0.5cm} 8.4.4 Fecal Samples .......................... 116
\hspace{0.5cm} 8.4.5 Analysis of Indirect Bioassay Samples ........ 116
8.5 Rapid Screening of Persons to Identify Radionuclide Intakes that Exceed the Clinical Decision Guide ............................. 117

9. Medical Management of Internally-Contaminated Persons ............................. 121
\hspace{0.5cm} 9.1 Introduction ................................ 121
\hspace{0.5cm} 9.2 General Clinical Guidance for the Treatment of Internal Contamination ................................ 122
\hspace{0.5cm} 9.3 Making Requests for Radiological Countermeasures ..... 124
\hspace{0.5cm} 9.4 Medical Management Decisions for Potentially-Contaminated Persons ............................. 125
\hspace{1cm} 9.4.1 Triage ................................ 125
\hspace{1cm} 9.4.2 Prioritizing Children and Pregnant Women ... 126
\hspace{1cm} 9.4.3 Medical Decisions During the Early Phases of a Radiation Incident ................................ 127
\hspace{1cm} 9.4.4 Choice of Decorporation Therapy for Internally-Deposited Radionuclides ............................. 128
\hspace{1cm} 9.4.5 Self-Treatment ................................ 129
\hspace{1cm} 9.4.6 Contaminated Wound Management ............................. 129
\hspace{1cm} 9.4.7 Using DTPA on Radionuclide-Contaminated Wounds ................................ 130
\hspace{0.5cm} 9.5 Medical Management of an Americium-241 Intake ............................. 131
\hspace{1cm} 9.5.1 Overview ................................ 131
\hspace{1cm} 9.5.2 Treatment ................................ 131
\hspace{1cm} 9.5.3 Medical Follow-Up After Treatment ............................. 134
\hspace{0.5cm} 9.6 Medical Management of a Cesium-137 Intake ............................. 134
\hspace{1cm} 9.6.1 Overview ................................ 134
\hspace{1cm} 9.6.2 Treatment ................................ 135
\hspace{1cm} 9.6.3 Medical Follow-Up After Treatment ............................. 135
\hspace{0.5cm} 9.7 Medical Management of a Cobalt-60 Intake ............................. 135
\hspace{1cm} 9.7.1 Overview ................................ 135
\hspace{1cm} 9.7.2 Treatment ................................ 138
\hspace{1cm} 9.7.3 Medical Follow-Up After Treatment ............................. 138
\hspace{0.5cm} 9.8 Medical Management of an Iodine-131 Intake ............................. 138
\hspace{1cm} 9.8.1 Overview ................................ 138
\hspace{1cm} 9.8.2 Treatment ................................ 140
\hspace{1cm} 9.8.3 Medical Follow-Up After Treatment ............................. 140
9.9 Medical Management of an Iridium-192 Intake ..........140
  9.9.1 Overview .................................................140
  9.9.2 Treatment .............................................145
  9.9.3 Medical Follow-Up After Treatment .................145

9.10 Medical Management of a Plutonium-238 or -239 Intake .................................................145
  9.10.1 Overview .............................................145
  9.10.2 Treatment .............................................146
  9.10.3 Medical Follow-Up After Treatment .................146

9.11 Medical Management of a Radium-226 Intake ..........146
  9.11.1 Overview .............................................146
  9.11.2 Treatment .............................................147
  9.11.3 Medical Follow-Up After Treatment .................147

9.12 Medical Management of a Strontium-90 Intake ..........147
  9.12.1 Overview .............................................147
  9.12.2 Treatment .............................................147
  9.12.3 Medical Follow-Up After Treatment .................150

9.13 Medical Management of a Uranium-235 or -238 Intake 150
  9.13.1 Overview .............................................150
  9.13.2 Treatment .............................................153
  9.13.3 Medical Follow-Up After Treatment .................153

10. Social, Psychological and Communication Issues Associated with Screening and Monitoring a Population .................................................155
  10.1 Introduction ..............................................155
  10.2 General Approach .........................................156
  10.3 Program and Center Names ...............................156
  10.4 Enlisting the Public as a Partner .......................156
  10.5 Communicating with Members of the Public .............157
  10.6 Proactive Approach .......................................157
  10.7 Information Hotlines .....................................158
  10.8 Special Services, Approaches and Materials for Children .................................................159
  10.9 Persons with Reproductive and Fertility Concerns ....160
  10.10 Other Special Populations ...............................161
  10.11 Addressing Staff Concerns and Information Needs ....161
  10.12 Staff Support ............................................162
  10.13 Training Exercises .......................................162
  10.14 Understanding and Addressing Responder Concerns and Information Needs .................................................163

11. Long-Term Follow-Up of Individuals .......................165
  11.1 Identification of the Population to be Followed .......165
  11.2 Classification of Persons to be Monitored or Followed .168
  11.3 Follow-Up Procedures ....................................171
<table>
<thead>
<tr>
<th>12. Scalability</th>
<th>172</th>
</tr>
</thead>
<tbody>
<tr>
<td>13. Assessment of Current Capacity in the United States to Perform Population Screening, Decontamination and Monitoring for Internal Contamination</td>
<td>180</td>
</tr>
<tr>
<td>13.1 Availability of Equipment and Resources</td>
<td>181</td>
</tr>
<tr>
<td>13.2 Laboratory Capabilities</td>
<td>182</td>
</tr>
<tr>
<td>13.3 Training Needs on Use of Equipment</td>
<td>183</td>
</tr>
<tr>
<td>13.4 Radiation Volunteers to Support Population Screening</td>
<td>185</td>
</tr>
<tr>
<td>13.5 Biodosimetry</td>
<td>186</td>
</tr>
<tr>
<td>13.6 Conclusions</td>
<td>187</td>
</tr>
<tr>
<td>14. Conclusions and Recommendations</td>
<td>188</td>
</tr>
<tr>
<td>14.1 Recommendations for Planning</td>
<td>188</td>
</tr>
<tr>
<td>14.2 Recommendations Related to Screening and Treatment of a Population for Internal Contamination</td>
<td>189</td>
</tr>
<tr>
<td>14.3 Recommendations for Additional Work</td>
<td>190</td>
</tr>
<tr>
<td>Appendix A. Radiological Properties of Radionuclides Considered in this Report</td>
<td>192</td>
</tr>
<tr>
<td>Appendix B. How to Perform a Radiation Survey for Contamination: Instructions for Workers</td>
<td>202</td>
</tr>
<tr>
<td>B.1 Screening Survey</td>
<td>202</td>
</tr>
<tr>
<td>B.2 Complete Whole-Body Survey</td>
<td>203</td>
</tr>
<tr>
<td>B.3 Most Common Mistakes Made During the Survey</td>
<td>204</td>
</tr>
<tr>
<td>Appendix C. How to Distinguish Between Alpha, Beta and Gamma Radiation Using a Geiger-Muller Survey Meter</td>
<td>205</td>
</tr>
<tr>
<td>C.1 Determining the Presence of an Alpha-Emitting Radionuclide Using Only a Geiger-Muller Survey Meter</td>
<td>206</td>
</tr>
<tr>
<td>C.2 Determining the Presence of Strontium-90 (or other pure beta emitters) Using a Pancake Geiger-Muller Survey Meter</td>
<td>206</td>
</tr>
<tr>
<td>Appendix D. Survey and Registry Forms</td>
<td>208</td>
</tr>
<tr>
<td>D.1 Contamination Survey Sheet</td>
<td>208</td>
</tr>
<tr>
<td>D.2 Registry Form</td>
<td>211</td>
</tr>
<tr>
<td>D.3 ATSDR Rapid Response Registry Survey Form ATSDR Rapid Response Registry Survey Form</td>
<td>214</td>
</tr>
<tr>
<td>Appendix E. How to Perform Decontamination at Home</td>
<td>216</td>
</tr>
</tbody>
</table>
Appendix F. Using Geiger-Muller Survey Meters to Assess Internal Contamination for Selected Gamma-Emitting Radionuclides ........................................218

Appendix G. Collection and Preparation of Biological Samples for Radioanalysis ..........................228
G.1 Urine Samples .........................................................228
G.2 Main Collection Issues ...........................................228

Appendix H. Shipping of Biological Samples .............231
H.1 Introduction ..........................................................231
H.2 Regulatory Information: Brief Summary ..............231
H.3 Definitions ............................................................232
H.4 General Shipping Guidelines for Clinical, Diagnostic and Exempt Biological Samples ............232
H.5 Specific Shipping Guidelines for Clinical, Diagnostic and Exempt Biological Samples ...........234
H.6 Website Links for Some Commercial Shippers ......234

Appendix I. Population Screening and Monitoring Implications of Two Urban Contamination Incidents ........................................235
I.1 Background ............................................................235
I.2 Overview of Two Cases ..............................................236
  I.2.1 Goiânia, Brazil ..................................................236
  I.2.2 London, United Kingdom ........................................236

Appendix J. Pregnancy Categories for Drug Use ..............238

Appendix K. Emergency Phone Numbers for Government Officials to Request Assistance Following a Radiological or Nuclear Incident ........................................239

Glossary .................................................................240

Abbreviations and Acronyms ........................................247

References ...............................................................248

The NCRP ...............................................................264

NCRP Publications ....................................................273